-
1.发明授权COMBINATIONS COMPRISING EPOTHILONES AND PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USES THEREOF 有权与埃博霉素和蛋白酪氨酸激酶抑制剂和使用它们的组合PHARAMAZEUTISCHE
公开(公告)号：EP1819331B1
公开(公告)日：2009-10-14
申请号：EP05852316.8
申请日：2005-11-28
申请人： Novartis AG , NOVARTIS-PHARMA GMBH
发明人： HUANG, Jerry, Min-Jian , JOHRI, Anandhi, Ranganathan , LINNARTZ, Ronald, Richard , MCSHEEHY, Paul, M., J.
IPC分类号： A61K31/426 , A61K31/519 , A61K31/436 , A61P35/00
CPC分类号： A61K45/06 , A61K31/426 , A61K31/436 , A61K31/519 , A61K2300/00
摘要： The invention relates to a combination which comprises: (a) an epothilone; and (b) a protein tyrosine kinase inhibitor; and optionally (c) a derivative of rapamycin; for simultaneous, separate or sequential use, in particular, for the delay of progression or treatment of a proliferative disease, especially cancer.
-
公开(公告)号：EP1773334A1
公开(公告)日：2007-04-18
申请号：EP05776218.9
申请日：2005-07-25
申请人： Novartis AG , NOVARTIS-PHARMA GMBH
IPC分类号： A61K31/427 , A61P35/00
CPC分类号： A61K45/06 , A61K31/427 , A61K2300/00
摘要： The invention relates to combinations of (a) an epothilone with (b) two or more other antineoplastic agents for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease.
-
3.发明公开COMBINATIONS COMPRISING EPOTHILONES AND PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USES THEREOF 有权与埃博霉素和蛋白酪氨酸激酶抑制剂和使用它们的组合PHARAMAZEUTISCHE
公开(公告)号：EP1819331A1
公开(公告)日：2007-08-22
申请号：EP05852316.8
申请日：2005-11-28
申请人： Novartis AG , NOVARTIS-PHARMA GMBH
发明人： HUANG, Jerry, Min-Jian , JOHRI, Anandhi, Ranganathan , LINNARTZ, Ronald, Richard , MCSHEEHY, Paul, M., J.
IPC分类号： A61K31/426 , A61K31/519 , A61K31/436 , A61P35/00
CPC分类号： A61K45/06 , A61K31/426 , A61K31/436 , A61K31/519 , A61K2300/00
摘要： The invention relates to a combination which comprises: (a) an epothilone; and (b) a protein tyrosine kinase inhibitor; and optionally (c) a derivative of rapamycin; for simultaneous, separate or sequential use, in particular, for the delay of progression or treatment of a proliferative disease, especially cancer.
-
公开(公告)号：EP1469847A1
公开(公告)日：2004-10-27
申请号：EP03729249.7
申请日：2003-01-13
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： A61K31/427 , A61K31/513 , A61K31/7068 , A61P35/00
CPC分类号： A61K31/427 , A61K31/513 , A61K31/7068 , A61K31/7072 , A61K45/06 , A61K2300/00
摘要： Disclosed is a combination which comprises (a) an antineoplastic antimetabolite and (b) an epothilone derivative of formula (I), wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino, aminomethyl or methylthio, and Z is O or a bond, and optionally at least one pharmaceutically acceptable carrier and/or, optionally, a standard anti-diarrheal, for simultaneous, separate or sequential use, in particular for the treatment of a proliferative disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal.
-
-
-
搜索结果
4 条记录 (耗时 0.01 秒)
